Publications by authors named "Rodeina Challand"

Claim this Profile
P
Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI-751): Results From a Randomized Phase 1 Trial.
Jeffrey N Hausfeld, Rodeina Challand, Kristi McLendon, Nathaniel Macapagal, Pam Bruce-Staskal

Clin Pharmacol Drug Dev· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iraqi regulatory authority current system and experience with biosimilars.
Khalid K Al-Kinani, Mazin J Ibrahim, Ruaa F Al-Zubaidi, Manal M Younus, Samir H Ramadhan, Rodeina Challand

Regul Toxicol Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars: where we were and where we are.
Rodeina Challand, Hazel Gorham, John Constant

J Biopharm Stat· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.
Cornelius F Waller, Vladimir F Semiglazov, Sergei Tjulandin, Dmitry Bentsion, Stephen Chan, Rodeina Challand

Onkologie· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Cornelius F Waller, Miguel Bronchud, Stuart Mair, Rodeina Challand

Ann Hematol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Cornelius F Waller, Miguel Bronchud, Stuart Mair, Rodeina Challand

Ann Hematol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis